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Introduction
Congestive heart failure (CHF) is an increasin-
gly widespread, costly and deadly disease, frequen-
tly named as epidemics of the XXI century. The
population of patients with CHF is growing and the
clinical spectrum of this group is changing with
markedly increasing subgroup of patients with pre-
served left ventricle ejection fraction (LVEF) [1, 2].
Despite advancement in modern treatment, mor-
tality rate in CHF patients, even those with predo-
minant diastolic dysfunction, remains high [3].
Approximately 50–60% of CHF patients will die wi-
thin 5 years of diagnosis. The prognosis worsens
with advancement of heart failure and the mortali-
ty rate in patients in NYHA class IV is as high as
50% per year. The mode of death depends mainly
on the NYHA functional class. Patients with less ad-
vanced CHF more frequently die suddenly, while
those in NYHA class IV are more likely to die of
pump failure [4, 5].
Early neurohumoral activation with sympathe-
tic overdrive interplaying with progressive hemo-
dynamic changes constitutes the main feature of
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heart failure independently of its etiology [6]. Even
though diagnosis of heart failure is based on symp-
toms with supporting evidence from imaging tech-
niques, the abnormalities in electrocardiographic
parameters significantly contribute to overall clini-
cal picture and clinical decisions. Continuous am-
bulatory Holter ECG monitoring is not considered
as a basic diagnostic method in the diagnosis of
CHF, however, it may serve as a valuable tool in
risk stratification. Several ECG parameters reflec-
ting underlying structural disease, electrical insta-
bility or autonomic nervous system imbalance may
be evaluated during Holter monitoring. Recent
years brought an increased interest in evaluation
of dynamic Holter-derived ECG markers reflecting
changes in heart rate and ventricular repolarization
behavior. The possibility of evaluation of dynamic
parameters and the ability of prolonged ECG mo-
nitoring in the ambient setting when the patients
are involved in their daily activities constitute the
main advantages of Holter analysis as compared to
standard surface ECG.
Traditional ECG risk predictors:
Heart rhythm, heart rate, arrhythmia
Heart rhythm
With no doubt surface 12-leads ECG remains
as one of the most useful tests in the diagnosis and
prognosis of CHF patients, providing data on the
heart rhythm, heart rate, and morphological chan-
ges in subsequent ECG curve’s components. The
presence of atrial fibrillation, sinus tachycardia or
wide QRS is related to worse prognosis. Ambula-
tory ECG monitoring allows for detecting paroxy-
smal arrhythmias, evaluating heart rate and dyna-
mics of arrhythmia giving insight to electrical acti-
vity of the heart during daily activities and during
night hours.
Atrial fibrillation (AF) is markedly more pre-
valent in CHF patients than in general population
[7]. In mild to moderate CHF the prevalence of AF
is estimated at 10–15% while in patients with more
advanced heart failure (in NYHA class IV) AF is
present in up to 50% of patients [8]. Heart failure
predisposes to AF and on the other hand AF may
worsen the prognosis of CHF patients significantly
aggravating heart failure symptoms. Several mecha-
nistic links between heart failure and AF include
volume-related atrial dilation, increased dispersion
of refractoriness in atria, catecholamine-induced
atrial fibrosis, and atrial channel remodeling [9].
There are conflicting data as to whether the pre-
sence of chronic atrial fibrillation is an independent
predictor for an increased mortality in heart failure
[10–19]. AF was found to be an independent pre-
dictor of mortality in the Framingham study [10].
In heart failure populations of the Vasodilators in
Heart Failure Trial (V-HeFT) [11] and the Prospec-
tive Randomized Study of Ibopamine on Mortality
and Efficacy (PRIME) [12] studies, AF was not iden-
tified as a significant predictor of mortality, whereas
analysis of data from the Studies of Left Ventricular
Dysfunction (SOLVD) showed that AF was a signi-
ficant predictor of mortality as well as a predictor of
CHF hospitalizations [13]. Data from the Carvedilol
or Metoprolol European Trial (COMET) further ad-
ded to controversy by showing that AF was not pre-
dictive of mortality in heart failure patients [14]. On
the other hand, new occurrence of AF, especially
coinciding with heart failure decompensation was
shown to be a marker of worse prognosis [20].
As both rate control and rhythm control stra-
tegies are nowadays accepted in management of AF
patients, prolonged Holter recording is useful for
monitoring appropriate ventricular response rate.
Criteria for adequate rate control vary with patient
age but usually achieving ventricular rates betwe-
en 60 and 80 beats per minute at rest and between
90 and 115 beats per minute during moderate exer-
cise is indicated [21]. Tachycardia-related unfavo-
rable impact of AF on CHF has been recognized for
years, however the question whether tachycardia
itself or heart rate irregularity related to AF are
responsible for the worsening of heart failure re-
mains open [22]. On the other hand, data exists in-
dicating that lower, and not higher rates in AF pa-
tients, may be associated with worse prognosis [23].
In a subpopulation of 77 patients with advanced he-
art failure and AF from PRIME II study, lower
heart rate (< 80 bpm) was an independent predic-
tor of all-cause mortality during a mean of 3.3 years
follow up (HR = 2.9; CI = 1.4–5.8, p = 0.002).
Heart rate
Heart rate is probably the easiest ECG para-
meter to assess, however the results of different
studies evaluating its prognostic value yield conflic-
ting results. Unfavorable tachycardia is a common
feature in CHF related to sympathetic overdrive.
The adequate control of the heart rate is essential
in all, not only AF patients, with heart failure. Pro-
longed heart rate monitoring is nowadays included
in home-monitoring systems in CHF patients, be-
ing one of the markers of the need for therapy mo-
dification [24]. High resting heart rate is well ac-
cepted risk predictor for all-cause mortality, but its
relation to cardiac and sudden death remains
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controversial. Similarly, no consensus exists on the
high risk cut off value of heart rate [25–27]. Last
decade brought ongoing interest in evaluation of
possible benefits of pharmacological heart rate re-
duction. Beta blockers have been documented to
reduce total mortality as well as sudden death. As
documented by metaanalyses, reduction in heart
rate achieved with beta blockers use was related
to better survival in CHF patients [28, 29]. The hi-
gher heart rate reduction was, the higher benefit
in context of mortality risk was observed. In the
CIBIS Trial the heart rate reduction was the most
powerful multivariate predictor of survival [30].
Subsequent CIBIS II trial documented that both
baseline heart rate as well as heart rate reduction
were independently associated with outcome in
CHF patients [31]. It is worth emphasizing that the
majority of data from clinical trials indicating unfa-
vorable impact of resting tachycardia on outcome
in CHF patients is based on heart rate assessed
either during physical examination or from surface
ECG. Suprisingly, in respect to CHF patients few
data is available on the prognostic value of mean
heart rate assessement on Holter monitoring, which
should be more reproducible than a single heart
measurement during a clinical visit. On the other
hand studies based on Holter monitoring showed
that not only high resting heart rate but also heart
rate range during 24 hours, expressed by simple
parameter as delta heart rate, may identify patients
at risk of progressive pump failure death [32, 33].
Delta heart rate, defined as a maximum circadian
change in heart rate over 24 hours during Holter
monitoring was independently related to death due
to pump failure in a cohort of 190 patients with CHF
in NYHA class II–III (HR = 3.7, CI = 1.7–8.2, p =
= 0.0013 for D heart rate £ 50 bpm [32]. Similarly,
in a study of Baker and Koeling based on 355 patients
with dilated cardiomyopathy not only mean heart rate
but also the heart rate range during Holter monitoring
were predictive of mortality (RR = 0.99, p = 0.008
per bpm). Patients with heart rate range equal or less
than 76 bpm had significantly worse survival as com-
pared to those with higher values [33].
Ventricular premature beats
Ventricular premature beats (VPB) as well as
their complex form like couplets or ventricular ta-
chycardia (VT) runs are frequently observed in pa-
tients with CHF. The presence of premature ven-
tricular beats has been documented in up to 85% of
patients with severe heart failure [34–36]. Relation-
ship between ventricular arrhythmia and sudden
death is not clear, however the majority of trials
showed a significant correlation between the presen-
ce of nonsustained VT and cardiac death [37–40].
In Captopril-Digoxin Multicenter Study [37] VPB,
couplets and nsVT were univariate predictors of
total mortality. The presence of at lest 2 episodes
of nsVT was related with 3-fold increase in total
mortality, and was an independent predictor of sud-
den death. In V-HeFT II study [38] nsVT and pairs
identified patients with increased mortality. GESI-
CA trial [39] documented that nsVT was associa-
ted with increased risk for both all-cause mortali-
ty, and sudden death. There is also data demonstra-
ting that length, but not the rate, of nsVT increases
the risk of major arrhythmic events [41]. Sponta-
neous sustained ventricular tachycardia is infrequ-
ent in Holter recordings, but if present, predicts
sudden death [42]. Even though ventricular tachy-
cardia is considered as a marker of arrhythmic
events, its role as a risk stratifier for both arrhyth-
mic and non-arrhythmic death may be supported by
observation from MADIT II trial where appropria-
te therapy by an ICD for VT/VF was associated with
an increased risk for heart failure and non-sudden
death [43].
Holter-derived risk predictors
related with autonomic nervous
system and repolarization
Heart rate variability (Table 1)
Heart rate variability (HRV) is a measure of the
cyclic variation of normal-to-normal RR intervals
that reflects cardiac autonomic function and may be
considered as a marker of sympathetic and parasym-
pathetic influence on the modulation of heart rate.
Therefore, evaluation of HRV has become one of
the integral component of autonomic nervous sys-
tem assessment in different subsets of patients,
especially in those with underlying structural he-
art disorders. Patients with CHF, even those with
predominant diastolic dysfunction, have decreased
spontaneous heart rate variability [44, 45]. The
extent of HRV reduction correlates with the advan-
cement of CHF expressed by measurements of
ejection fraction, NYHA class or BNP levels [46].
Decreased HRV has been for years considered
as an independent and strong marker of risk for all
cause mortality or heart failure death [47], while
data on predicting sudden death is conflicting. It is
difficult to compare the predictive value of HRV
parameters in prognosis of CHF patients, as they
have been analyzed by different methods and in
different time intervals [48–61]. Early reports on
316
Cardiology Journal 2008, Vol. 15, No. 4
www.cardiologyjournal.org
Table 1. Prognostic value of heart rate variability (HRV) and heart rate turbulence (HRT) in patients with
congestive heart failure.
Author No. of patients Studied population Follow-up (av.) Results
HRV
Nolan et al. [49] 443 UK Heart Study 482 days Annual mortality
CHF, class I–III NYHA; of 51.4% for SDNN < 50 ms;
mean LVEF 41% SDNN < 50 ms — RR = 9.4
(4.1–20.6) for total mortality
and RR = 2.54 (1.50–4.30)
for heart failure death;
not predictive
for sudden death
Ponikowski et al. [50] 102 CHF, NYHA class II–IV; 584 days SDNN, SDANN and LF
mean LVEF 26%;  predictive for mortality
76% ischemic etiology 1 year mortality 22% in pts
with SDNN < 100 ms
Boveda et al. [51] 190 CHF, NYHA class II–IV; 22 months SDNN < 67 predictive
Galinier et al. [52] mean LVEF 28%, for all-cause mortality
45% ischemic etiology  (RR = 2.5, CI = 1.5–4.2)
InLF < 3.3 predictive
for sudden death
(RR = 2.8, CI = 1.2–8.6)
Bilchick et al. [53] 127 CHF-STAT Study 34 months SDNN < 65.3 predictive
II–III NYHA class; for all-cause mortality
mean LVEF 26%; (RR = 3.72) and borderline
75% ischemic etiology significant (p = 0.08) for
sudden death (RR = 2.40)
Fauchier et al. [61] 116 Idiopathic dilated 53 months SDNN < 100 ms
cardiomyopathy; predictive for
mean LVEF 34% sudden death
La Rovere et al. [55] 202 CHF mild to moderate; 3 years Controlled breathing
mean LVEF 24% LF < 13 ms2 predictive
for sudden death
Hadase et al. [56] 54 CHF; mean LVEF 40% 19.8 months VLFln < 6 predictive
in survivors for all cause mortality
HRT
Grimm et al. [67] 242 Marburg Study 41 months TO as predictor of
Dilated idiopathic  transplant free survival.
cardiomyopathy; TO and TS — only univariate
 mean LVEF 30% predictors of major
arrhythmic events
Koyama et al. [66] 50 CHF; mean EF 39%, 26 months Abnormal TS
 32% ischemic etiology (£ 3 ms/RR)
predictive for death
and hospitalizations
for heart failure
(HR = 10.2, CI = 3.2–37.5)
Kawasaki et al. [70] 104 Hypertrophic 27 months HRT failed to predict
cardiomyopathy death and arrhythmic events
Moore et al. [68] 358 UK Heart Study 5 years Abnormal TS
CHF, class I–III NYHA; (£ 2.5 ms/RR)
mean LVEF 41% predicts heart failure
decompensation
Klingenheben et al. [74] 114 Frankfurt Dilated 22 months HRT not predictive
Cardiomyopathy for arrhythmic events
database; mean
LVEF 28%
Cygankiewicz et al. [73] 607 MUSIC Trial 44 months Abnormal TS
CHF, NYHA class II–III; (£ 2.5 ms/RR)
mean LVEF 37%, and HRT2 predictive
50% ischemic etiology for all-cause mortality,
sudden death and heart failure
death (for HRT2 HR = 2.52;
2.25 and 4.11, respectively
for modes of death)
CHF — congestive heart failure; NYHA — New York Heart Association; LVEF — left ventricle ejection fraction, SDNN — standard deviation of NN,
SDANN — standard deviation of averaged NN intervals, LF — low frequency, RR — relative risk, CI — confidence interval, VLF — very low frequency,
TO — turbulence onset, TS — turbulence slope, EF — ejection fraction, HR — hazard ratio, HRT — heart rate turbulence
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predictive value of HRV showed that reduced HRV
parameters were related with 20-fold increased risk
of death in patients awaiting heart transplantation
[48]. Standard deviation of NN intervals (SDNN) is
the best known, best validated and easiest HRV
parameter, however different cut-offs were propo-
sed as predictive. In the UK-Heart Study SDNN
below 50 ms was associated with death due to pro-
gressive heart failure, but failed to predict sudden
death [49]. The other studies indicated SDNN be-
low 100 ms [50], 67 ms [51], or 65.3 ms [53] as pre-
dictors of mortality in CHF patients. There is a con-
stant trend in all the published studies toward high
prognostic value of depressed HRV in predicting
heart failure death and all-cause mortality.
Even more controversies exist in terms of fre-
quency domain components. The findings of these
studies are difficult to compare mainly due to diffe-
rent methodological approaches. Decreased LF and
VLF component are the most frequently reported
HRV spectral measures related with mortality in
CHF patients [55, 56]. In a study by La Rovere et
al. [55] low frequency power measured from short
term recordings during controlled breathing was
found to be a powerful predictor of sudden death in
202 patients with moderate to severe CHF [55].
Different components of spectral analysis were
documented to be related to different types of de-
ath. In a group of 330 CHF patients in NYHA class
I–III decreased night-time VLF was related to pro-
gressive heart failure, while decreased night-time
LF values were associated with sudden death [57].
Non-linear measures of heart rate variability were
also reported as markers of mortality in CHF pa-
tients [58, 59]. Recently published study by Maestri
et al. [60] aimed to compare several nonlinear HRV
methods, in predicting mortality in patients with
CHF. The authors of this study demonstrated that
despite differences in prognostic values, asses-
sment of nonlinear indices provides important pro-
gnostic information on top of clinical data.
Prognostic role of HRV in prediction of sudden
death remains controversial, however the majority
of studies demonstrated no prognostic significance
of HRV in predicting sudden cardiac death (SCD).
Only a study of Fauchier et al. [61] showed that
reduced SDNN < 100 ms was independent risk
predictor of sudden death and arrhythmic events in
patients with dilated cardiomyopathy. The paucity
of clear evidence for the association between de-
pressed HRV parameters and SCD might be due to
the difficulty in categorizing the sudden or arrhy-
thmic nature of death, but also could be due to lack
of strong evidence for this association. The auto-
nomic nervous system operates differently in va-
rious patients depending not only on the disease but
also on the advancement of the disease process.
Heart rate variability parameters successfully pre-
dict CHF worsening and total mortality in CHF pa-
tients indicating that autonomic dysfunction is a part
of the overall clinical picture in such patients, but
these parameters seem to have little or no progno-
stic significance for predicting SCD in such patients.
Heart rate turbulence (Table 1)
Heart rate turbulence (HRT), defined as a bi-
phasic reaction of sinus node in response to a pre-
mature ventricular beat, consisting of an early ac-
celeration and subsequent deceleration of heart
rate, was introduced into electrocardiology in 1999,
and since then has been proved as a powerful pre-
dictor of mortality in postinfarction patients [62–65].
Blunted HRT reaction has been observed in vario-
us subgroups of patients with cardiomyopathies and
heart failure independently on the underlying etio-
logy [66–69]. Only patients with hypertrophic car-
diomyopathy did not differ in terms of HRT values
from control subjects [70]. It has been suggested
that HRT, considered as vagally-dependent effec-
tive measure of baroreflex sensitivity [71, 72] rela-
ted to the advancement of heart failure, might be
used as a marker of congestive heart failure staging
[69, 72].
Data on the predictive value of HRT in patients
with cardiomyopathies and/or heart failure remain
limited. The majority of data related abnormal HRT
with progression of disease [66–68, 73]. In the Mar-
burg Study [67] turbulence onset was found a si-
gnificant predictor of transplant free survivals in 242
patients with idiopathic cardiomyopathy. In a study
of Koyama [66] including 50 patients with heart fa-
ilure (both of ischemic and idiopathic etiology) ab-
normal turbulence slope defined as > 3 ms/RR was
predictive for progression of heart failure including
deaths and hospitalizations due to CHF worsening.
These observations were confirmed by data from
UK Heart Study in patients with mild to moderate
heart failure where abnormal turbulence slope was
found to be an independent risk predictor of death
due to decompensated heart failure [68]. Studies in-
cluding patients with nonischemic cardiomyopathy
failed to demonstrate the usefulness of HRT in pre-
dicting arrhythmic events [67, 70, 74]. Our group
as the first documented that abnormal HRT, espe-
cially turbulence slope predicts not only total mor-
tality and heart failure progression, but also sudden
death in 607 CHF patients in NYHA class II–III of
both ischemic and non-ischemic etiology, from
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MUSIC Trial. Abnormal heart rate turbulence was
found in our study to be predictive for mortality,
regardless of the classification of mode of death.
However, consistent with postulated mechanisms
of HRT relating this phenomenon to abnormal ba-
roreflex sensitivity and autonomic imbalance, ab-
normal HRT showed a trend toward a stronger as-
sociation with heart failure death than with sud-
den death. Similarly to previous reports,
turbulence slope was a significant risk stratifier for
all modes of death, while turbulence onset was pre-
dictive only for total mortality and heart failure
death (Fig. 1) [73].
Repolarization dynamics (Table 2)
Static measures of QT duration and QT disper-
sion have been for years considered as risk factors
in patients with CHF, however their predictive va-
lue was usually overwhelmed by clinical covariates
[75–79]. Several different methods have been descri-
bed to evaluate dynamicity of repolarization [80–82].
Our group reported increased number of peaks of
prolonged QTc interval, e.g. the proportion of
QTc intervals above the prespecified threshold
(QTc > 500 ms) as a marker of life-threatening ar-
rhythmias in postinfarction patients [81]. Similarly
to coronary patients increased percentage of QT
peaks was found in patients with dilated cardiomy-
opathy as compared to healthy subjects [83]. In re-
cent years, QT/RR slope analyzed from long term
Holter recordings has become the most popular
method to evaluate QT adaptation to changing heart
Table 2. Prognostic value of QT dynamicity in patients with congestive heart failure.
Author No. of patients Studied population Follow-up Results
Pathak et al. [88] 175 CHF, class II–III NYHA, av. 30 months QT/RR > 0.28 predictive
43% ischemic etiology; for total mortality
mean LVEF 28% (HR = 2.2, CI = 1.24–3.9)
and for sudden death
(HR = 3.4, CI = 1.43–8.40)
Iacoviello et al. [90] 179 Idiopathic dilated 39 months QTe/RR > 0.19 predictive
cardiomyopathy; for major arrhythmic events
mean LVEF 34% HR = 1.38 (1.02–1.85)
for 0.05 increase in QT/RR
Watanabe et al. [89] 121 CHF, 84% in NYHA 34 ± 17 months QT/RR > 0.17 predictive
class III–IV, for cardiac death
 30% ischemic etiology; (HR = 4.73, CI = 1.37–18.7)
mean LVEF 41% in survivors and for sudden death
(HR = 11.2, CI = 3.28–21.4)
Cygankiewicz et al. [91] 542 MUSIC Trial CHF, 44 months Daytime QTe/RR > 0.22
in NYHA class II–III, predictive for total and
 49% ischemic etiology; cardiac mortality
 mean LVEF 37% (HR = 1.58, CI = 1.07–2.32),
not predictive for sudden death
CHF — congestive heart failure; NYHA — New York Heart Association; LVEF — left ventricle ejection fraction, HR — hazard ratio, CI — confidence
interval, QTe — QTend
Figure 1. Cumulative probability of death according to
abnormal values of turbulence onset (TO) and turbulen-
ce slope (TS) in the MUSIC Study.
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rate. Steeper slope indicates inappropriate shorte-
ning of QT interval at higher heart rate and exces-
sive lenghtening of QT during low heart rate- both
mechanisms significantly contributing to the risk of
arrhythmic events (Fig. 2). From the pathophysio-
logical point of view steeper QT/RR indicates de-
creased vagal tone and increased sympathetic acti-
vity reflecting the higher vulnerability of myocar-
dium to arrhythmias. At the cellular level
sympathetic stimulation prolongs ventricular refrac-
toriness. Therefore, increased QT slope represents
increased vulnerability of myocardial substrate to
its modulation by autonomic nervous system. Incre-
ased QT/RR slopes were observed in patients at risk
of cardiac death including postinfarction patients,
long QT syndrome patients, and patients with dila-
ted cardiomyopathy [82–87]. Abnormal QT dynami-
city was found to predict cardiac events in various
populations, mainly in postinfarction patients [82, 84].
Data on prognostic value of QT dynamicity in pa-
tients with CHF is limited. In a study by Pathak et
al. [88] increased QTe/RR slope assessed over 24
hours was found to be predictive for total mortality
and sudden death in a population of 175 patients with
chronic heart failure due to ischemic (43%) or idio-
Figure 2. Exemplary QT/RR slopes of a low-risk (A) and
a high risk (B) patient. Steeper slopes are observed in
a high risk patient as compared to a low-risk; QTa —
QTapex; QTe — QTend.
B
A
pathic (57%) cardiomyopathy with mean LVEF
27.8%. Of note, the predictive value of QT/RR was
higher for prediction of sudden death than of ove-
rall mortality. The second study by Watanabe et al.
[89] confirmed that QT/RR slope > 0.17 is pre-
dictive of total mortality (HR = 4.73, CI =
= 1.37–18.7, p = 0.013) and also independently as-
sociated with sudden death (HR = 11.2, CI =
= 3.28–21.4, p = 0.001) in patients with CHF. In-
dependent prognostic value of QT dynamicity in pa-
tients with idiopathic dilated cardiomyopathy was
reported by Iacoviello et al. [90] who found that
abnormal QT dynamicity was significantly associa-
ted with arrhythmic events (VT/VF or SCD) during
mean 39-month follow up. At multivariate analysis
only the QTe-slope (> 0.19), decreased LVEF and
nsVT were independent predictors of poor outco-
me. The combination of these 3 variables identi-
fied the group at the highest risk. It is worth em-
phasizing that QT/RR allowed for identification of
higher risk group among patients with low EF (< 35%).
The probability of arrhythmic events in patients
with LVEF < 35%, nsVT and increased QT/RR
slope was as high as 40%. In our MUSIC Trial in
CHF patients with mild to moderate CHF we docu-
mented that abnormal QT dynamics expressed as in-
creased daytime QT/RR slopes (> 0.20 for QTa and >
> 0.22 for QTe) were independently associated with
increased total mortality in multivariate analysis after
adjustment for clinical covariates with respective ha-
zard ratios 1.57 and 1.58 p = 0.002. None of the dy-
namic repolarization parameters was associated with
increased risk of SD in the entire population [91].
QT interval being influenced by a variety of fac-
tors may change not only in terms of its duration but
also morphology. QT variability is an ECG phenome-
non consisting of beat-to-beat changes in repolariza-
tion duration and morphology appearing without the
2:1 pattern typical for T-wave alternans. These beat-
to-beat changes in the T wave amplitude and shape
as well as in QT duration, similarly to what is obse-
rved in case of QT dynamics, can be analyzed by
several novel computerized ECG methods enabling
for detection and quantification of subtle, microvolt-
level changes, which otherwise remain undetected
by the naked eye [92].
There is an increasing interest in the analysis
of QT variability in Holter recordings. Berger et al.
developed a time-stretching algorithm to quantify
changes in repolarization duration and morphology
and documented that patients with CHF have incre-
ased variability when compared to age-matched
healthy subjects [93]. Increased beat-to-beat chan-
ges in repolarization duration and morphology
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predisposes to electrical instability of the myocar-
dium and may favor initiation and maintenance of
reentry arrhythmias. As recently documented by
Piccirillo et al. [94], abnormal QT variability can
identify high SCD risk group among asymptomatic
patients with only mild to moderate left ventricu-
lar dysfunction. In a group of 396 patients with con-
gestive heart failure due to ischemic cardiomyopa-
thy with LVEF between 35% and 40% and NYHA class
1, QT variability index greater or equal to the 80th
percentile (–0.47) indicated an independent high
risk for SCD with hazard ratio of 4.6 (1.5–13.4, p =
= 0.006). This finding might suggest that abnormal
QT variability may serve as a marker to identify po-
ssible candidates to ICD therapy among patients
with a moderately depressed LVEF, however this
requires further prospective studies.
Conclusions and recommendations
Electrocardiographic parameters based on am-
bulatory Holter monitoring have been documented
to be independent risk predictors of total mortality
and progression of heart failure. It seems that mo-
dern Holter monitoring may serve also as a valuable
tool for investigating factors that may contribute to
the mechanism of sudden death. It is widely accep-
ted that structural changes reflecting myocardial
substrate are better identified by means of imaging
techniques, Holter monitoring on the other hand
provides complementary information on myocardial
vulnerability and autonomic nervous system. Never-
theless, data regarding its prognostic value in pre-
diction of SCD remains controversial and the positi-
ve predictive value of the majority of Holter-based
risk stratifiers is low. Therefore, combining of elec-
trocardiographic stratification with assessment of
myocardial substrate may provide the complex insi-
ght into interplay between factors contributing to
death. On the other hand, negative predictive value
of Holter risk markers is usually high, therefore it
may be used to identify low risk patients.
It is not likely that one specific ECG risk pre-
dictor could be found to predict total and sudden
death in a heterogeneous population of patients with
congestive heart failure. Therefore, it seems that
the combination of various ECG risk markers co-
vering different arms of SCD risk triangle may be
considered as better approach (Fig. 3).
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